Real-World Data on Semaglutide and Tirzepatide for Weight Loss in Rheumatic Patients
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide are well-established for managing type 2 diabetes and are increasingly prescribed for weight loss. Despite their growing use, there is limited real-world data on how these medications are initiated and their weight-loss efficacy specifically within patients suffering from rheumatic and musculoskeletal diseases (RMDs).
Study Design
Results
The study observed significant weight loss across both GLP-1 RA groups. Patients initiating tirzepatide achieved an average weight reduction of 15.7% from baseline over 6 months, compared to 10.5% for those on semaglutide (p<0.001). Among patients transitioning from semaglutide to tirzepatide, an additional mean weight loss of 5.2% was observed within 3 months post-transition. The most significant finding was that 78% of patients with rheumatic and musculoskeletal diseases achieved at least 10% total body weight loss on tirzepatide, demonstrating its potent efficacy in this specific cohort. Initiation patterns showed 65% of patients started on semaglutide, while 35% began with tirzepatide, with 12% of the semaglutide group subsequently transitioning to tirzepatide within the study period.
Why It Matters
This real-world data underscores the substantial weight-loss benefits of GLP-1 RAs, particularly tirzepatide, in patients with rheumatic and musculoskeletal diseases, a population often challenged by weight management due to disease activity and medication side effects. The findings suggest that these agents can be highly effective in improving metabolic health in this vulnerable group. These insights could inform clinical guidelines, promoting earlier and more widespread use of GLP-1 RAs in RMD patients who could benefit from significant weight reduction. Future research should focus on long-term outcomes, impact on disease activity, and cost-effectiveness in larger, prospective human trials.